Hook & thesis
Kaspi.kz (KSPI) is a classic event-driven value setup: the board has recommended a cash dividend that creates a palpable downside floor while management is executing an M&A playbook that could materially expand the company outside Kazakhstan. At $74.20, KSPI sits close to its 52-week low of $70.05 and well below its 52-week high of $101.53. With a market cap of $14.26 billion, a P/E of 6.92 and a return-focused board proposal, the risk-reward profile now favors a measured long exposure ahead of two near-term catalysts - an April 15, 2026 annual meeting where shareholders will vote on the recommended dividend and the regulatory close of the Rabobank Turkey acquisition expected mid-2026.
Why the market should care
Kaspi is not a one-product fintech; it operates three integrated platforms - Payments, Marketplace and Fintech - centered on the Kaspi Super App. That integration drives repeat engagement, low customer acquisition costs and high conversion rates between payments and marketplace transactions. The market cares because Kaspi has historically turned this engagement into strong profitability: the company’s valuation implies roughly $2.06 billion in net income (market cap $14.26B / P/E 6.92), which tells you the business is already cash-generative. The next leg of growth is geographic - a Turkish banking and payments franchise could add scale, volume and fee income and materially lift multiples if executed cleanly.
Key data points and context
- Current price: $74.20 (intraday snapshot).
- Market cap: $14.26 billion.
- P/E: 6.92; P/B: 3.44.
- 52-week range: $70.05 - $101.53.
- Shares outstanding: ~192.2 million; float ~145.8 million.
- Board recommendation: annual meeting on 04/15/2026 includes a proposed dividend of 850 KZT per common share (company proposal), which I estimate at roughly $1.80 per ADS using recent FX approximations - a visible cash return that acts as downside support if approved.
- Strategic M&A: signed to acquire Rabobank A.Ş. (Turkey) with transaction closure expected mid-2026 pending regulatory approvals (announcement 11/28/2025).
- Debt and capital markets activity: a $650 million Eurobond priced 03/21/2025, 6.25% coupon due 2030 - signals active balance sheet management to fund growth.
- Technicals: RSI ~49 (neutral), MACD histogram turned positive indicating bullish momentum; recent 10-day SMA ~$73.29 vs current price $74.20.
- Short interest: latest settlement shows ~1,553,558 shares short with days-to-cover ~3.29, not extreme but meaningful.
Valuation framing
On simple trailing earnings math the market is valuing Kaspi at ~7x earnings. For a fintech with integrated marketplace and payment rails that has historically generated high returns on equity and strong cash flow, sub-8x looks conservative. The low multiple partly reflects geopolitical and governance overhangs that have drawn litigation and investor scrutiny and the perception of concentrated country risk. But the board’s move to return cash (proposed 850 KZT dividend) sets a tangible floor under the stock: even if growth slows, shareholders receive cash while the company continues to pursue an inorganic growth vector in Turkey.
Compare this to Kaspi's own history: the stock traded over $100 less than a year ago and was marked up on growth optimism for its core Kazakh market. If Turkey contributes incremental fees and deposits at scale, forward multiple could re-rate from the high-single digits to mid-teens; conversely, failed integration or regulatory pushback would justify the current multiple or lower.
Catalysts
- 04/15/2026 annual general meeting - shareholder vote on the recommended 850 KZT dividend and governance items. Approval would make the dividend effectively the downside cushion.
- Regulatory clearance and close of Rabobank Turkey acquisition - expected mid-2026. Successful close + first-quarter integration metrics would be a positive re-rating event.
- Quarterly operational release (next financial results) that confirms deposits, merchant penetration and loan performance in Kazakhstan; any beat on margins or improved guidance would help sentiment.
- Debt markets / refinancing updates - the company’s $650M Eurobond (priced 03/21/2025) and subsequent balance sheet actions could influence perceived financial flexibility.
Trade plan (actionable)
Trade idea: take a long position at $74.20 with a hard stop at $69.00 and a primary target of $105.00. This is a directional, event-driven long where the payoff is tied to dividend approval and the Turkey acquisition closing and beginning to show contribution.
- Entry: $74.20 (execute on weakness or immediate participation).
- Stop loss: $69.00 - placed just below the 52-week low of $70.05 to limit downside if the market sells off on governance or sanctions headlines.
- Targets:
- Target 1 (mid-term): $90.00 - realistic within ~45 trading days if AGM confirms dividend and the market begins to price in Turkey synergies.
- Target 2 (long-term): $105.00 - achievable within ~180 trading days on successful Turkish regulatory close, early integration metrics and re-rating from sub-8x to low-teens P/E.
- Horizon:
- Short term (10 trading days): use this window to buy into any post-AGM dip or to trim into early strength post-dividend confirmation.
- Mid term (45 trading days): expect Target 1 if initial Turkey-close optimism and better-than-expected quarterly metrics occur.
- Long term (180 trading days): hold toward Target 2 aiming to capture valuation re-rate on successful cross-border execution and revenue/fee uplift.
Position sizing & execution notes
Because of geopolitical and legal overhangs, this trade is medium risk. Size positions so that a move to the stop loss represents acceptable portfolio risk. Consider scaling in: initial tranche at $74.20 and add on pullbacks toward the $72 area, keeping the aggregated stop loss at $69.00.
Risks and counterarguments
Below are the main risks that could invalidate the thesis and move the stock lower:
- Regulatory or political risk: Kaspi operates principally in Kazakhstan and the proposed Turkey acquisition requires approvals; regulators could slow or block the deal, which would crush the upside case.
- Governance and legal overhang: ongoing class action litigation and past allegations of undisclosed related-party transactions can prolong investor skepticism and suppress multiples.
- Sanctions / geopolitical exposure: any credible link to sanctioned entities or additional sanctions risk would materially impair cross-border operations, de-risking capital flows and partnerships.
- Integration risk: Turkey is a new geographic market culturally and operationally; poor integration could dilute margins and require higher provisioning or capital infusion.
- Balance sheet risk: the company has used debt markets (a $650M Eurobond, 6.25% coupon) to fund corporate purposes; any deterioration in earnings or deposit flight could stress liquidity and leverage ratios.
Counterargument
A reasonable opposing view is that the market is correctly pricing concentrated political and sanction risks, and that even with a dividend the long-term multiple should remain compressed until regulatory clarity and clean governance are demonstrated. If the Turkey deal is delayed materially or the AGM rejects the dividend or reduces it, equity holders could face renewed downside pressure. That scenario supports a conservative allocation or staying on the sidelines until clearer progress on M&A and governance is seen.
What would change my mind
I would reduce conviction if any of the following occurs: 1) the AGM on 04/15/2026 fails to approve the recommended dividend or the payout is materially cut; 2) regulators materially delay or block the Rabobank Turkey transaction beyond mid-2026 with unclear remedy; 3) new credible evidence surfaces of sanctions-related exposure or undisclosed related-party transactions that meaningfully change cash flow prospects. Conversely, my conviction would increase if post-close Turkey integration metrics show rapid deposit growth, merchant sign-ups and fee accretion, or if management provides a clear, capital-light path to scale in Turkey.
Conclusion
Kaspi.kz presents an asymmetric setup: a visible dividend floor (company-proposed 850 KZT) limits downside while the pending Turkish acquisition offers meaningful upside if regulatory approval and integration proceed. The stock’s current valuation (market cap $14.26B, P/E ~6.9) already reflects skepticism; this trade buys the skepticism at a controlled price with a clear stop loss and defined multi-horizon targets tied to concrete catalysts. For disciplined traders comfortable with geopolitical and integration risk, enter at $74.20, protect at $69.00, and look for re-rating into the mid-teens multiple should Turkey begin contributing to top-line and fee growth.